{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:23:31Z","timestamp":1791314611367,"version":"4.3.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40265-025-02276-9","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:45:50Z","timestamp":1769849150000},"page":"335-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4477-3633","authenticated-orcid":false,"given":"Pamela","family":"Abdayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6259-8234","authenticated-orcid":false,"given":"Claudia","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-8310","authenticated-orcid":false,"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"1","key":"2276_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"21","key":"2276_CR2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339.","journal-title":"N Engl J Med"},{"issue":"6","key":"2276_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611\u201325.","journal-title":"J Clin Oncol"},{"issue":"48","key":"2276_CR4","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985\u201393.","journal-title":"Oncotarget"},{"issue":"7955","key":"2276_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","volume":"616","author":"W Hill","year":"2023","unstructured":"Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, et al. Lung adenocarcinoma promotion by air pollutants. Nature. 2023;616(7955):159\u201367.","journal-title":"Nature"},{"issue":"2","key":"2276_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"3, Supplement 1","key":"2276_CR7","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","volume":"20","author":"JCH Yang","year":"2025","unstructured":"Yang JCH, Kim YJ, Lee SH, Liu B, Ostapenko YV, Lu S, et al. 4O: amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study. J Thorac Oncol. 2025;20(3, Supplement 1):S6-8.","journal-title":"J Thorac Oncol"},{"key":"2276_CR8","unstructured":"He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, et al. Neoadjuvant osimertinib for resectable EGFR-mutated non\u2013small cell lung cancer. J Clin Oncol. 2025;0(0):JCO-25-00883."},{"issue":"10","key":"2276_CR9","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non\u2013small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830\u201340.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2276_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585\u201397.","journal-title":"N Engl J Med"},{"issue":"8","key":"2276_CR11","doi-asserted-by":"publisher","first-page":"R292","DOI":"10.1016\/S0960-9822(01)00167-1","volume":"11","author":"S Bogdan","year":"2001","unstructured":"Bogdan S, Kl\u00e4mbt C. Epidermal growth factor receptor signaling. Curr Biol. 2001;11(8):R292-295.","journal-title":"Curr Biol"},{"issue":"5","key":"2276_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52.","journal-title":"Cancers"},{"issue":"2","key":"2276_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","volume":"142","author":"RP Graham","year":"2018","unstructured":"Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med. 2018;142(2):163\u20137.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2276_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdt418","volume":"25","author":"M Beau-Faller","year":"2014","unstructured":"Beau-Faller M, Prim N, Ruppert AM, Nanni-Met\u00e9llus I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25(1):126\u201331.","journal-title":"Ann Oncol"},{"issue":"5676","key":"2276_CR15","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.","journal-title":"Science"},{"issue":"36","key":"2276_CR16","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumours to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2276_CR17","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdz399","volume":"30","author":"H Yoshioka","year":"2019","unstructured":"Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB\/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(12):1978\u201384.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"2","key":"2276_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213\u201322.","journal-title":"Lancet Oncol"},{"issue":"27","key":"2276_CR19","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JCH, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(27):3327\u201334.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"1","key":"2276_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/annonc\/mds214","volume":"24","author":"A Inoue","year":"2013","unstructured":"Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin\u2013paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54\u20139.","journal-title":"Ann Oncol"},{"issue":"9","key":"2276_CR21","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","volume":"26","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877\u201383.","journal-title":"Ann Oncol"},{"issue":"1","key":"2276_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","volume":"88","author":"D Rangachari","year":"2015","unstructured":"Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer Amst Neth. 2015;88(1):108\u201311.","journal-title":"Lung Cancer Amst Neth."},{"issue":"11","key":"2276_CR23","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2276_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares L, Tan EH, O\u2019Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270\u20137.","journal-title":"Ann Oncol"},{"issue":"7","key":"2276_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M\u2013positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"key":"2276_CR26","first-page":"109","volume":"8","author":"M Santarpia","year":"2017","unstructured":"Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffin\u00e0 MG, D\u2019Aveni A, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer Auckl NZ. 2017;8:109\u201325.","journal-title":"Lung Cancer Auckl NZ."},{"issue":"12","key":"2276_CR27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.23.01521","volume":"42","author":"J Remon","year":"2024","unstructured":"Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, et al. Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non-small-cell lung cancer. J Clin Oncol. 2024;42(12):1350\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2276_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472784","volume":"45","author":"G La Cava","year":"2025","unstructured":"La Cava G, Cortellini A, Rotow JK, Bauman JR. Navigating first-line treatment options for patients with epidermal growth factor receptor-positive non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2025;45(3):e472784.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"2276_CR29","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jtho.2025.09.162","volume":"20","author":"Y Shi","year":"2025","unstructured":"Shi Y, Xing L, Zhang Z, Wu L, Zhuang W, Li X, et al. MA08.06 comparison of asandeutertinib and osimertinib in EGFR-mutated NSCLC with brain metastases: interim analysis of the ESAONA pivotal study. J Thorac Oncol. 2025;20(10):S89-90.","journal-title":"J Thorac Oncol"},{"issue":"27","key":"2276_CR30","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon\u2013small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022;40(27):3162\u201371.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2276_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022;10(11):1019\u201328.","journal-title":"Lancet Respir Med"},{"issue":"26","key":"2276_CR32","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","volume":"41","author":"BC Cho","year":"2023","unstructured":"Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JCH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(26):4208\u201317.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"4","key":"2276_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(24)00417-X","volume":"13","author":"Y Shi","year":"2025","unstructured":"Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, et al. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study. Lancet Respir Med. 2025;13(4):327\u201337.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2276_CR34","first-page":"764","volume":"16","author":"A Passaro","year":"2021","unstructured":"Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2021;16(5):764\u201373.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer."},{"issue":"8","key":"2276_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499\u2013514.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2276_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.","journal-title":"Mol Cancer"},{"key":"2276_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","volume":"147","author":"S Schmid","year":"2020","unstructured":"Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer Amst Neth. 2020;147:123\u20139.","journal-title":"Lung Cancer Amst Neth."},{"key":"2276_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102824","volume":"130","author":"C Corvaja","year":"2024","unstructured":"Corvaja C, Passaro A, Attili I, Aliaga PT, Spitaleri G, Signore ED, et al. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development. Cancer Treat Rev. 2024;130:102824.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"2276_CR39","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","volume":"21","author":"MJ Niederst","year":"2015","unstructured":"Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The Allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(17):3924\u201333.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"5","key":"2276_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189413","volume":"1880","author":"S Liu","year":"2025","unstructured":"Liu S, Xu T, Cao X, Li H, Jin R. Histological transformation in lung cancer: mechanisms, clinical characteristics, and therapeutic approaches. Biochim Biophys Acta BBA Rev Cancer. 2025;1880(5):189413.","journal-title":"Biochim Biophys Acta BBA Rev Cancer."},{"issue":"9","key":"2276_CR41","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fonc.2019.01044","volume":"11","author":"X Zhu","year":"2019","unstructured":"Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;11(9):1044.","journal-title":"Front Oncol"},{"issue":"9","key":"2276_CR42","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"issue":"10","key":"2276_CR43","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, et al. Concurrent RB1 and TP53 alterations define a\u00a0subset of EGFR-mutant lung cancers at risk for\u00a0histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784\u201393.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2276_CR44","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/cancers15112998","volume":"15","author":"SL Feldt","year":"2023","unstructured":"Feldt SL, Bestvina CM. The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications. Cancers. 2023;15(11):2998.","journal-title":"Cancers"},{"issue":"31","key":"2276_CR45","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JCH, et al. Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36(31):3101\u20139.","journal-title":"J Clin Oncol"},{"key":"2276_CR46","doi-asserted-by":"crossref","unstructured":"Oxnard GR, Cantarini M, Frewer P, Hawkins G, Peters J, Howarth P, et al. SAVANNAH: a phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib. J Clin Oncol. 2019;37(15_suppl):TPS9119\u2013TPS9119.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9119"},{"issue":"4","key":"2276_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JCH, Yu H, Kim SW, Saka H, Horn L, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507\u201316.","journal-title":"Ann Oncol"},{"issue":"3","key":"2276_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373\u201386.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2276_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2217\/fon-2021-1406","volume":"18","author":"EF Smit","year":"2022","unstructured":"Smit EF, Dooms C, Raskin J, Nadal E, Tho LM, Le X, et al. INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance. Future Oncol Lond Engl. 2022;18(9):1039\u201354.","journal-title":"Future Oncol Lond Engl."},{"key":"2276_CR50","doi-asserted-by":"publisher","first-page":"S1419","DOI":"10.1016\/j.annonc.2022.08.054","volume":"33","author":"J Mazieres","year":"2022","unstructured":"Mazieres J, Kim TM, Lim BK, Wislez M, Dooms C, Finocchiaro G, et al. LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: initial results from the INSIGHT 2 study. Ann Oncol. 2022;33:S1419\u201320.","journal-title":"Ann Oncol"},{"issue":"1","key":"2276_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","volume":"13","author":"RJ Hartmaier","year":"2023","unstructured":"Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, et al. Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON. Cancer Discov. 2023;13(1):98\u2013113.","journal-title":"Cancer Discov"},{"issue":"10","key":"2276_CR52","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/1078-0432.CCR-22-3318","volume":"29","author":"CK Liam","year":"2023","unstructured":"Liam CK, Ahmad AR, Hsia TC, Zhou J, Kim DW, Soo RA, et al. Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(10):1879\u201386.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"2276_CR53","doi-asserted-by":"crossref","unstructured":"Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, et al. Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): results from a randomized phase 3 SACHI study. J Clin Oncol. 2025;43(17_suppl):LBA8505\u2013LBA8505.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8505"},{"issue":"5","key":"2276_CR54","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.22.00739","volume":"41","author":"DR Camidge","year":"2023","unstructured":"Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105\u201315.","journal-title":"J Clin Oncol"},{"issue":"34","key":"2276_CR55","doi-asserted-by":"publisher","first-page":"S1670","DOI":"10.1016\/j.annonc.2023.10.594","volume":"1","author":"H Horinouchi","year":"2023","unstructured":"Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, et al. 515MO Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): final efficacy and safety updates. Ann Oncol. 2023;1(34):S1670.","journal-title":"Ann Oncol"},{"issue":"5","key":"2276_CR56","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","volume":"36","author":"H Horinouchi","year":"2025","unstructured":"Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, et al. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025;36(5):583\u201391.","journal-title":"Ann Oncol"},{"key":"2276_CR57","doi-asserted-by":"crossref","unstructured":"Camidge DR, Raimbourg J, Lee YG, de Miguel MJ, Hollebecque A, Kim TM, et al. Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase 1 study. J Clin Oncol. 2025;43(16_suppl):8512\u20138512.","DOI":"10.1200\/JCO.2025.43.16_suppl.8512"},{"issue":"15_suppl","key":"2276_CR58","doi-asserted-by":"publisher","first-page":"9006","DOI":"10.1200\/JCO.2021.39.15_suppl.9006","volume":"39","author":"J Bauml","year":"2021","unstructured":"Bauml J, Cho BC, Park K, Lee KH, Cho EK, Kim DW, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-na\u00efve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol. 2021;39(15_suppl):9006.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2276_CR59","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1200\/JCO.2023.41.16_suppl.9134","volume":"41","author":"SH Lee","year":"2023","unstructured":"Lee SH, Cho BC, Han JY, Cho EK, Lee JS, Lee KH, et al. Amivantamab and lazertinib in treatment-na\u00efve EGFR-mutated advanced non\u2013small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS. J Clin Oncol. 2023;41(16_suppl):9134\u20139134.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2276_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","volume":"20","author":"B Besse","year":"2025","unstructured":"Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, et al. Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A. J Thorac Oncol. 2025;20(5):651\u201364.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2276_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","volume":"16","author":"X Le","year":"2021","unstructured":"Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205\u201315.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2276_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/COC.0000000000000976","volume":"46","author":"J Deluce","year":"2023","unstructured":"Deluce J, Maj D, Verma S, Breadner D, Boldt G, Raphael J. Efficacy and toxicity of combined inhibition of EGFR and VEGF in patients with advanced non-small cell lung cancer harboring activating EGFR mutations: a systematic review and meta-analysis. Am J Clin Oncol. 2023;46(3):87\u201393.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"2276_CR63","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jtho.2024.11.032","volume":"20","author":"K Nakagawa","year":"2025","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, et al. RELAY: final overall survival for erlotinib plus ramucirumab or placebo in untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2025;20(4):487\u201399.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2276_CR64","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.24.00533","volume":"43","author":"X Le","year":"2025","unstructured":"Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, et al. A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial). J Clin Oncol. 2025;43(4):403\u201311.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2276_CR65","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12(2):403\u20137.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2276_CR66","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387\u2013401.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"2276_CR67","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","volume":"42","author":"S Park","year":"2024","unstructured":"Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, et al. Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or translocated non\u2013small-cell lung cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024;42(11):1241\u201351.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2276_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111722","volume":"28","author":"T Zhong","year":"2025","unstructured":"Zhong T, Zhang L, Huang Z, Pang X, Jin C, Liu W, et al. Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience. 2025;28(3):111722.","journal-title":"iScience."},{"key":"2276_CR69","doi-asserted-by":"crossref","unstructured":"HARMONi-A Study Investigators, Fang W, Zhao Y, Luo Y, Yang R, Huang Y, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561\u201370.","DOI":"10.1001\/jama.2024.10613"},{"key":"2276_CR70","doi-asserted-by":"crossref","unstructured":"Goldman JW, Passaro A, Laskin J, Rodrigues-Abreu D, Calles A, Bazhenova L, et al. PL02.12 Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi. J Thorac Oncol. 2025;20(10):S2\u20133.","DOI":"10.1016\/j.jtho.2025.09.017"},{"issue":"2","key":"2276_CR71","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/cancers15020504","volume":"15","author":"H Chhouri","year":"2023","unstructured":"Chhouri H, Alexandre D, Grumolato L. Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer. Cancers. 2023;15(2):504.","journal-title":"Cancers"},{"issue":"1","key":"2276_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380.","journal-title":"Cell"},{"issue":"11","key":"2276_CR73","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","volume":"16","author":"M Mikubo","year":"2021","unstructured":"Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol. 2021;16(11):1798\u2013809.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"2276_CR74","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1038\/ncomms10690","volume":"19","author":"M Ramirez","year":"2016","unstructured":"Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016;19(7):10690.","journal-title":"Nat Commun"},{"key":"2276_CR75","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1038\/ncomms3467","volume":"4","author":"AO Pisco","year":"2013","unstructured":"Pisco AO, Brock A, Zhou J, Moor A, Mojtahedi M, Jackson D, et al. Non-darwinian dynamics in therapy-induced cancer drug resistance. Nat Commun. 2013;4:2467.","journal-title":"Nat Commun"},{"issue":"3","key":"2276_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104321","volume":"30","author":"X Yao","year":"2025","unstructured":"Yao X, Gao C, Sun C, Chen ZS, Zhuang J. Epigenetic code underlying EGFR-TKI resistance in non-small cell lung cancer: elucidation of mechanisms and perspectives on therapeutic strategies. Drug Discov Today. 2025;30(3):104321.","journal-title":"Drug Discov Today"},{"issue":"22","key":"2276_CR77","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021;81(22):5589\u201395.","journal-title":"Cancer Res"},{"issue":"2","key":"2276_CR78","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124\u201336.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2276_CR79","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115\u201323.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2276_CR80","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JCH, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"key":"2276_CR81","doi-asserted-by":"crossref","unstructured":"Valdiviezo N, Okamoto I, Hughes BGM, Ahmed S, Wu L, Hu J, et al. 4O First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes. ESMO Open [Internet]. 2024 Mar 1 [cited 2025 June 30];9. https:\/\/www.esmoopen.com\/article\/S2059-7029(24)00351-X\/fulltext.","DOI":"10.1016\/j.esmoop.2024.102583"},{"key":"2276_CR82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510308","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Yang JCH, Liu Y, Valdiviezo N, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2510308.","journal-title":"N Engl J Med"},{"key":"2276_CR83","doi-asserted-by":"publisher","first-page":"S1733","DOI":"10.1016\/j.annonc.2025.09.091","volume":"36","author":"PA J\u00e4nne","year":"2025","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Yang JCH, Zhu J, Lee CK, et al. LBA77 FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) \u00b1 platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC. Ann Oncol. 2025;36:S1733\u20134.","journal-title":"Ann Oncol"},{"key":"2276_CR84","doi-asserted-by":"crossref","unstructured":"Yang JC, Robichaux J, Planchard D, Kobayashi K, Lee CK, Sugawara S, et al. MA12.03 FLAURA2: resistance, and impact of baseline TP53 alterations in patients treated with 1L osimertinib \u00b1 platinum-pemetrexed. J Thorac Oncol. 2024;19(10, Supplement):S101\u20132.","DOI":"10.1016\/j.jtho.2024.09.184"},{"issue":"7","key":"2276_CR85","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.23.02219","volume":"42","author":"PA J\u00e4nne","year":"2024","unstructured":"J\u00e4nne PA, Planchard D, Kobayashi K, Cheng Y, Lee CK, Valdiviezo N, et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2024;42(7):808\u201320.","journal-title":"J Clin Oncol"},{"key":"2276_CR86","doi-asserted-by":"crossref","unstructured":"Lee CK, Cheng Y, Laktionov K, Kim SW, Kato T, Wang J, et al. 9P First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs). ESMO Open [Internet]. 2024 [cited 2025 Nov 27];9. https:\/\/www.esmoopen.com\/article\/S2059-7029(24)00356-9\/fulltext.","DOI":"10.1016\/j.esmoop.2024.102588"},{"issue":"16","key":"2276_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70083","volume":"13","author":"W Tian","year":"2024","unstructured":"Tian W, Niu L, Zhou R, Wang Z, Ning J, Lu R, et al. Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Med. 2024;13(16):e70083.","journal-title":"Cancer Med"},{"key":"2276_CR88","doi-asserted-by":"crossref","unstructured":"Wang J, Wang ZJ, Zhong J, Zhao WH, Wu L, Chu Q, et al. PL02.09 Aumolertinib plus chemotherapy for NSCLC with EGFR and concomitant tumour suppressor genes (ACROSS 2): phase III study. J Thorac Oncol. 2025;20(10):S1\u20132.","DOI":"10.1016\/j.jtho.2025.09.016"},{"issue":"16","key":"2276_CR89","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398.","journal-title":"N Engl J Med"},{"issue":"9","key":"2276_CR90","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","volume":"35","author":"E Felip","year":"2024","unstructured":"Felip E, Cho BC, Guti\u00e9rrez V, Alip A, Besse B, Lu S, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a\u00a0secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805\u201316.","journal-title":"Ann Oncol"},{"key":"2276_CR91","doi-asserted-by":"publisher","first-page":"S1245","DOI":"10.1016\/j.annonc.2024.08.2297","volume":"35","author":"B Besse","year":"2024","unstructured":"Besse B, Lee SH, Lu S, Stroyakovskiy D, Yazici O, Cid JRR, et al. LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: an early analysis from the phase III MARIPOSA study. Ann Oncol. 2024;35:S1245\u20136.","journal-title":"Ann Oncol"},{"issue":"3","key":"2276_CR92","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S1556-0864(25)00205-9","volume":"20","author":"N Girard","year":"2025","unstructured":"Girard N, Li W, Spira A, Feldman J, Mak M, Sauder MB, et al. 10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: early success of the COCOON trial. J Thorac Oncol. 2025;20(3):S14\u20136.","journal-title":"J Thorac Oncol"},{"issue":"30","key":"2276_CR93","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.24.01001","volume":"42","author":"NB Leighl","year":"2024","unstructured":"Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593\u2013605.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2276_CR94","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jtho.2025.09.161","volume":"20","author":"SC Scott","year":"2025","unstructured":"Scott SC, Dias JM, Liu B, Lim SM, Ono A, Calderon VG, et al. MA08.05 PALOMA-2: subcutaneous amivantamab administered every 4 weeks plus lazertinib in first-line EGFR-mutated advanced NSCLC. J Thorac Oncol. 2025;20(10):S89.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2276_CR95","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472792","volume":"45","author":"JW Carlisle","year":"2025","unstructured":"Carlisle JW, Wolner Z, Pannu S, Mitchell C, Hsu M, Aijaz A, et al. Bispecific antibodies in non-small cell lung cancer: from targeted innovation to real-world integration. Am Soc Clin Oncol Educ Book. 2025;45(3):e472792.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2276_CR96","doi-asserted-by":"publisher","first-page":"S804","DOI":"10.1016\/j.annonc.2024.08.1312","volume":"35","author":"YL Wu","year":"2024","unstructured":"Wu YL, Wang Z, Cheng Y, Fang J, Meng X, Pan Y, et al. 1255MO A phase II safety and efficacy study of PM8002\/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S804.","journal-title":"Ann Oncol"},{"key":"2276_CR97","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","volume":"163","author":"A Desai","year":"2022","unstructured":"Desai A, Abdayem P, Adjei AA, Planchard D. Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer. Lung Cancer Amst Neth. 2022;163:96\u2013106.","journal-title":"Lung Cancer Amst Neth"},{"issue":"21","key":"2276_CR98","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.23.00013","volume":"41","author":"A Passaro","year":"2023","unstructured":"Passaro A, J\u00e4nne PA, Peters S. Antibody-drug conjugates in lung cancer: recent advances and implementing strategies. J Clin Oncol. 2023;41(21):3747\u201361.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2276_CR99","doi-asserted-by":"publisher","first-page":"1332057","DOI":"10.3389\/fimmu.2023.1332057","volume":"4","author":"Q Chen","year":"2024","unstructured":"Chen Q, Jia G, Zhang X, Ma W. Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front Immunol. 2024;4(14):1332057.","journal-title":"Front Immunol"},{"issue":"1","key":"2276_CR100","doi-asserted-by":"publisher","first-page":"7406","DOI":"10.1038\/s41598-019-43678-6","volume":"9","author":"H Scharpenseel","year":"2019","unstructured":"Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, et al. EGFR and HER3 expression in circulating tumour cells and tumour tissue from non-small cell lung cancer patients. Sci Rep. 2019;9(1):7406.","journal-title":"Sci Rep"},{"key":"2276_CR101","doi-asserted-by":"crossref","unstructured":"Ha Y, Y G, H H, E F, J CHY, M R, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol [Internet]. 2023 Oct 12 [cited 2024 Oct 4];41(35). https:\/\/pubmed.ncbi.nlm.nih.gov\/37689979\/.","DOI":"10.1200\/JCO.23.01476"},{"key":"2276_CR102","doi-asserted-by":"crossref","unstructured":"Mok TSK, Yu HA, Lim SM, Okamoto I, Perol M, Novello S, et al. Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study. J Clin Oncol. 2025;43(16_suppl):8506\u20138506.","DOI":"10.1200\/JCO.2025.43.16_suppl.8506"},{"key":"2276_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102572","volume":"118","author":"C Parisi","year":"2023","unstructured":"Parisi C, Mahjoubi L, Gazzah A, Barlesi F. TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2023;118:102572.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"2276_CR104","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. 2025;43(3):260\u201372.","journal-title":"J Clin Oncol"},{"key":"2276_CR105","doi-asserted-by":"crossref","unstructured":"Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR\u2013mutated NSCLC. J Thorac Oncol. 2025;S1556086425007610.","DOI":"10.1016\/j.jtho.2025.06.002"},{"issue":"3","key":"2276_CR106","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","volume":"20","author":"X Le","year":"2025","unstructured":"Le X, Hendriks L, Morabito A, Bonanno L, Okamoto I, Goldman JW, et al. 1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. J Thorac Oncol. 2025;20(3):S2-4.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2276_CR107","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43(3):260\u201372.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"3","key":"2276_CR108","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/S1556-0864(25)00319-3","volume":"20","author":"E Nadal","year":"2025","unstructured":"Nadal E, Cheema PK, Wu YL, Ahn MJ, Tanizaki J, Gharagoozloo S, et al. 124TiP: TROPION-Lung15: a phase III study of datopotamab deruxtecan (Dato-DXd) \u00b1 osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. J Thorac Oncol. 2025;20(3):S87\u20138.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2276_CR109","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","volume":"31","author":"S Zhao","year":"2025","unstructured":"Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials. Nat Med. 2025;31(6):1976\u201386.","journal-title":"Nat Med"},{"issue":"16_suppl","key":"2276_CR110","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1200\/JCO.2025.43.16_suppl.8507","volume":"43","author":"L Zhang","year":"2025","unstructured":"Zhang L, Fang W, Li X, Wang Q, Meng X, Zheng W, et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): results from the randomized OptiTROP-Lung03 study. J Clin Oncol. 2025;43(16_suppl):8507.","journal-title":"J Clin Oncol"},{"key":"2276_CR111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512071","author":"W Fang","year":"2025","unstructured":"Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, et al. Sacituzumab tirumotecan in EGFR-TKI\u2013resistant, EGFR-mutated advanced NSCLC. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2512071.","journal-title":"N Engl J Med"},{"key":"2276_CR112","first-page":"S1728","volume":"36","author":"L Zhang","year":"2025","unstructured":"Zhang L, Fang WF, Wu L, Meng X, Yao Y, Zuo W, et al. LBA5 Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase III OptiTROP-Lung04 study. Ann Oncol. 2025;36:S1728\u20139.","journal-title":"Ann Oncol"},{"issue":"10","key":"2276_CR113","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G, Shum E, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025;43(10):1254\u201365.","journal-title":"J Clin Oncol"},{"key":"2276_CR114","unstructured":"Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR\u2013mutated NSCLC. J Thorac Oncol [Internet]. 2025 June 12 [cited 2025 July 12];0(0). https:\/\/www.jto.org\/article\/S1556-0864(25)00761-0\/fulltext."},{"key":"2276_CR115","doi-asserted-by":"crossref","unstructured":"Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. 2025 June 5 [cited 2025 July 12]. https:\/\/www.bmj.com\/content\/389\/bmj-2025-085680.","DOI":"10.1136\/bmj-2025-085680"},{"key":"2276_CR116","doi-asserted-by":"crossref","unstructured":"Fang W, Cheng Y, Chen Z, Wang W, Li Y, Yin Y, et al. Abstract CT247: updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study. Cancer Res. 2024;84(7_Supplement):CT247.","DOI":"10.1158\/1538-7445.AM2024-CT247"},{"issue":"7","key":"2276_CR117","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25(7):901\u201311.","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"2276_CR118","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.2025.43.16_suppl.3000","volume":"43","author":"A Lisberg","year":"2025","unstructured":"Lisberg A, Lu S, Hamilton EP, Wang Q, Rotow JK, Starodub A, et al. DB-1310, a HER3-targeted ADC, in pts with advanced solid tumours: preliminary results from the phase 1\/2a trial. J Clin Oncol. 2025;43(16_suppl):3000.","journal-title":"J Clin Oncol"},{"issue":"25","key":"2276_CR119","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(25):3000\u201311.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"6","key":"2276_CR120","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","volume":"14","author":"X Qin","year":"2024","unstructured":"Qin X, Ning W, Liu H, Liu X, Luo W, Xia N. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharm Sin B. 2024;14(6):2361\u201377.","journal-title":"Acta Pharm Sin B"},{"key":"2276_CR121","doi-asserted-by":"crossref","unstructured":"Segal NH, Girda E, Sohal D, Lakhani NJ, Olszanski AJ, Fong L, et al. A phase 1\/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumours, including colorectal cancer: Trial in progress update. J Clin Oncol. 2024;42(3_suppl):TPS239.","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS239"},{"issue":"9","key":"2276_CR122","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/vaccines11091460","volume":"11","author":"F Li","year":"2023","unstructured":"Li F, Wu H, Du X, Sun Y, Rausseo BN, Talukder A, et al. Epidermal growth factor receptor-targeted neoantigen peptide vaccination for the treatment of non-small cell lung cancer and glioblastoma. Vaccines. 2023;11(9):1460.","journal-title":"Vaccines"},{"key":"2276_CR123","doi-asserted-by":"crossref","unstructured":"Abstract 852: a novel EGFR neoantigen-specific mRNA cancer vaccine demonstrates immunogenicity and anti-tumour efficacy in human | Cancer Research | American Association for Cancer Research [Internet]. [cited 2025 June 21]. https:\/\/aacrjournals.org\/cancerres\/article\/85\/8_Supplement_1\/852\/755037\/Abstract-852-A-novel-EGFR-neoantigen-specific-mRNA.","DOI":"10.1158\/1538-7445.AM2025-852"},{"issue":"1","key":"2276_CR124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"key":"2276_CR125","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00047","volume":"9","author":"MF Chen","year":"2025","unstructured":"Chen MF, Jeng MY, Ma J, Agrawal P, Dunne E, Boe LA, et al. Outcomes after radiation for oligoprogressive disease sites in patients with EGFR-mutant lung cancer treated with osimertinib. JCO Precis Oncol. 2025;9:e2500047.","journal-title":"JCO Precis Oncol"},{"key":"2276_CR126","doi-asserted-by":"crossref","unstructured":"Catania C, Liu SV, Garassino M, Delmonte A, Scotti V, Cappuzzo F, et al. Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study. ESMO Open [Internet]. 2025 July 1 [cited 2025 July 7];10(7). https:\/\/www.esmoopen.com\/article\/S2059-7029(25)01195-0\/fulltext.","DOI":"10.1016\/j.esmoop.2025.105326"},{"issue":"7","key":"2276_CR127","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"HARMONi-A Study Investigators","year":"2024","unstructured":"HARMONi-A Study Investigators. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561\u201370.","journal-title":"JAMA"},{"issue":"1","key":"2276_CR128","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol Off J Eur Soc Med Oncol. 2024;35(1):77\u201390.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"2","key":"2276_CR129","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.resinv.2024.01.002","volume":"62","author":"T Araki","year":"2024","unstructured":"Araki T, Kanda S, Obara M, Agatsuma T, Kakizaki Y, Hama M, et al. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: a multicenter retrospective observational study. Respir Investig. 2024;62(2):262\u20138.","journal-title":"Respir Investig"},{"issue":"9944","key":"2276_CR130","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet Lond Engl. 2014;384(9944):665\u201373.","journal-title":"Lancet Lond Engl."},{"key":"2276_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108417","volume":"202","author":"MC Garassino","year":"2025","unstructured":"Garassino MC, He Y, Ahn MJ, Orlov SV, Potter V, Kato T, et al. Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025;202:108417.","journal-title":"Lung Cancer"},{"issue":"1","key":"2276_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100347","volume":"7","author":"J Mi","year":"2021","unstructured":"Mi J, Huang Z, Zhang R, Zeng L, Xu Q, Yang H, et al. Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer. ESMO Open. 2021;7(1):100347.","journal-title":"ESMO Open."},{"issue":"10","key":"2276_CR133","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jtho.2025.09.053","volume":"20","author":"PH Chen","year":"2025","unstructured":"Chen PH, Young TH, Hsieh MS, Hsu HH, Chen JS. OA07.04 molecular and early outcomes of a randomized phase II trial of primary tumour resection following EGFR TKI in metastatic NSCLC. J Thorac Oncol. 2025;20(10):S25.","journal-title":"J Thorac Oncol"},{"key":"2276_CR134","doi-asserted-by":"publisher","first-page":"S1729","DOI":"10.1016\/j.annonc.2025.09.086","volume":"36","author":"YY Elamin","year":"2025","unstructured":"Elamin YY, Gandhi S, Antonoff M, Gibbons D, Negrao MV, Cascone T, et al. LBA72 NorthStar: a phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2025;36:S1729.","journal-title":"Ann Oncol"},{"key":"2276_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107427","volume":"187","author":"A Schuler","year":"2024","unstructured":"Schuler A, Huser J, Schmid S, Sch\u00e4r S, Scherz A, Gautschi O, et al. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): a Swiss cohort study. Lung Cancer. 2024;187:107427.","journal-title":"Lung Cancer"},{"issue":"6","key":"2276_CR136","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/j.cllc.2017.04.002","volume":"18","author":"B Qiu","year":"2017","unstructured":"Qiu B, Liang Y, Li Q, Liu G, Wang F, Chen Z, et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18(6):e369\u201373.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"2276_CR137","doi-asserted-by":"publisher","first-page":"522","DOI":"10.7150\/jca.26494","volume":"10","author":"Q Xu","year":"2019","unstructured":"Xu Q, Liu H, Meng S, Jiang T, Li X, Liang S, et al. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. J Cancer. 2019;10(2):522\u20139.","journal-title":"J Cancer"},{"issue":"3","key":"2276_CR138","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/JTO.0b013e31827e1f83","volume":"8","author":"HA Yu","year":"2013","unstructured":"Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346\u201351.","journal-title":"J Thorac Oncol"},{"key":"2276_CR139","doi-asserted-by":"publisher","first-page":"S1420","DOI":"10.1016\/j.annonc.2022.08.055","volume":"33","author":"Z Piotrowska","year":"2022","unstructured":"Piotrowska Z, Ahn MJ, Pang YK, How SH, Kim SW, Voon PJ, et al. LBA53 ELIOS: a multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib. Ann Oncol. 2022;33:S1420\u20131.","journal-title":"Ann Oncol"},{"issue":"53","key":"2276_CR140","doi-asserted-by":"publisher","first-page":"39653","DOI":"10.1039\/D4RA05497K","volume":"14","author":"M Hu","year":"2024","unstructured":"Hu M, Chen X. A review of the known MTA-cooperative PRMT5 inhibitors. RSC Adv. 2024;14(53):39653\u201391.","journal-title":"RSC Adv"},{"issue":"12","key":"2276_CR141","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, Helali AE, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumours: results from phase I dose exploration. Ann Oncol. 2024;35(12):1138\u201347.","journal-title":"Ann Oncol"},{"issue":"6","key":"2276_CR142","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cllc.2021.06.006","volume":"22","author":"HA Yu","year":"2021","unstructured":"Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced\/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD). Clin Lung Cancer. 2021;22(6):601\u20136.","journal-title":"Clin Lung Cancer"},{"issue":"34","key":"2276_CR143","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","volume":"42","author":"JCH Yang","year":"2024","unstructured":"Yang JCH, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E, et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(34):4029\u201339.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2276_CR144","doi-asserted-by":"crossref","unstructured":"Peled N, Tufman A, Sequist LV, Pasello G, Wang Q, Antonuzzo L, et al. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. ESMO Open [Internet]. 2025 Oct 1 [cited 2025 Nov 29];10(10). https:\/\/www.esmoopen.com\/article\/S2059-7029(25)01676-X\/fulltext.","DOI":"10.1016\/j.esmoop.2025.105807"},{"issue":"34","key":"2276_CR145","doi-asserted-by":"publisher","first-page":"S847","DOI":"10.1016\/j.annonc.2023.09.2535","volume":"1","author":"W Fang","year":"2023","unstructured":"Fang W, Cappuzzo F, Goldman JW, Zhao Y, Huang Y, Anderson I, et al. 1504TiP HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment. Ann Oncol. 2023;1(34):S847.","journal-title":"Ann Oncol"},{"key":"2276_CR146","doi-asserted-by":"crossref","unstructured":"Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with egfr-mutated advanced non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(22):6644\u201352.","DOI":"10.1158\/1078-0432.CCR-19-1126"},{"key":"2276_CR147","doi-asserted-by":"crossref","unstructured":"Leite da Silva LF, Saldanha EF, de Menezes JSA, Halamy Pereira L, de Bragan\u00e7a Dos Santos JAR, Buonopane IR, et al. Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis. Oncologist. 2025;30(2):oyae344.","DOI":"10.1093\/oncolo\/oyae344"},{"issue":"1","key":"2276_CR148","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdp271","volume":"21","author":"A Avigdor","year":"2010","unstructured":"Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET\/CT scan is an effective regimen for advanced high-risk Hodgkin\u2019s lymphoma. Ann Oncol. 2010;21(1):126\u201332.","journal-title":"Ann Oncol"},{"issue":"11","key":"2276_CR149","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol. 2023;20(11):799\u2013813.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2276_CR150","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-024-02134-4","volume":"23","author":"D Vasseur","year":"2024","unstructured":"Vasseur D, Bigot L, Beshiri K, Fl\u00f3rez-Arango J, Facchinetti F, Hollebecque A, et al. Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development. Mol Cancer. 2024;23(1):221.","journal-title":"Mol Cancer"},{"issue":"1","key":"2276_CR151","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun. 2019;10(1):3991.","journal-title":"Nat Commun"},{"key":"2276_CR152","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","volume":"88","author":"X He","year":"2023","unstructured":"He X, Liu X, Zuo F, Shi H, Jing J. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Semin Cancer Biol. 2023;88:187\u2013200.","journal-title":"Semin Cancer Biol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02276-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:31:21Z","timestamp":1772771481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02276-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":152,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2276"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02276-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P. Abdayem received speaker honoraria from AstraZeneca, Netcancer, MSD, and travel grants from Pierre Fabre, Eli Lilly, Pfizer and Roche, outside the submitted work. C. Parisi declares no conflicts of interest that might be relevant to the contents of this manuscript. D. Planchard received honoraria from AstraZeneca, Abbvie, Bristol Myers Squibb, Daiichi-Sankyo, Merck, Novartis, Janssen, Pfizer, Roche, and Sanofi-Aventis and institutional financial fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, Abbvie, Janssen, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provided consent for publication of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No code was generated during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}